These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9085557)

  • 41. Inclusion complexation of p-hydroxybenzoic acid esters with 2-hydroxypropyl-beta-cyclodextrins. On changes in solubility and antimicrobial activity.
    Matsuda H; Ito K; Sato Y; Yoshizawa D; Tanaka M; Taki A; Sumiyoshi H; Utsuki T; Hirayama F; Uekama K
    Chem Pharm Bull (Tokyo); 1993 Aug; 41(8):1448-52. PubMed ID: 8403092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclodextrins as carriers for kavalactones in aqueous media: spectroscopic characterization of (S)-7,8-dihydrokavain and beta-cyclodextrin inclusion complex.
    Pescitelli G; Bilia AR; Bergonzi MC; Vincieri FF; Di Bari L
    J Pharm Biomed Anal; 2010 Aug; 52(4):479-83. PubMed ID: 20185265
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sulfobutyl ether β-cyclodextrin (Captisol(®) ) and methyl β-cyclodextrin enhance and stabilize fluorescence of aqueous indocyanine green.
    DeDora DJ; Suhrland C; Goenka S; Mullick Chowdhury S; Lalwani G; Mujica-Parodi LR; Sitharaman B
    J Biomed Mater Res B Appl Biomater; 2016 Oct; 104(7):1457-64. PubMed ID: 26251293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Slow-release of famotidine from tablets consisting of chitosan/sulfobutyl ether β-cyclodextrin composites.
    Anraku M; Hiraga A; Iohara D; Pipkin JD; Uekama K; Hirayama F
    Int J Pharm; 2015 Jun; 487(1-2):142-7. PubMed ID: 25882010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone.
    Tavornvipas S; Tajiri S; Hirayama F; Arima H; Uekama K
    Pharm Res; 2004 Dec; 21(12):2369-76. PubMed ID: 15648271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhancement of the aqueous solubility and masking the bitter taste of famotidine using drug/SBE-beta-CyD/povidone K30 complexation approach.
    Mady FM; Abou-Taleb AE; Khaled KA; Yamasaki K; Iohara D; Ishiguro T; Hirayama F; Uekama K; Otagiri M
    J Pharm Sci; 2010 Oct; 99(10):4285-94. PubMed ID: 20737636
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utility of nuclear magnetic resonance spectroscopy to characterize the structure of dexamethasone sodium phosphate inclusion complexes with cyclodextrins in solution and to analyze potential competitive effects.
    Echezarreta-López MM; Perdomo-López I; Estrada E; Vila-Jato JL; Torres-Labandeira JJ
    J Pharm Sci; 2002 Jun; 91(6):1536-47. PubMed ID: 12115852
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peak-less hypoglycemic effect of insulin glargine by complexation with maltosyl-β-cyclodextrin.
    Uehata K; Anno T; Hayashida K; Higashi T; Motoyama K; Hirayama F; Uekama K; Arima H
    Int J Pharm; 2012 Jan; 422(1-2):33-9. PubMed ID: 22020273
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system.
    Higashi T; Hirayama F; Misumi S; Arima H; Uekama K
    Biomaterials; 2008 Oct; 29(28):3866-71. PubMed ID: 18620750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative evaluation of the effect of cyclodextrins and pH on aqueous solubility of apigenin.
    Pápay ZE; Sebestyén Z; Ludányi K; Kállai N; Balogh E; Kósa A; Somavarapu S; Böddi B; Antal I
    J Pharm Biomed Anal; 2016 Jan; 117():210-6. PubMed ID: 26363816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biquinolino-modified beta-cyclodextrin dimers and their metal complexes as efficient fluorescent sensors for the molecular recognition of steroids.
    Liu Y; Song Y; Chen Y; Li XQ; Ding F; Zhong RQ
    Chemistry; 2004 Aug; 10(15):3685-96. PubMed ID: 15281152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ-cyclodextrin and its dissolution characteristics.
    Igami K; Ozawa M; Inoue S; Iohara D; Miyazaki T; Shinoda M; Anraku M; Hirayama F; Uekama K
    J Pharm Pharmacol; 2016 May; 68(5):646-54. PubMed ID: 26255976
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta-cyclodextrins and their solubilizing and stabilizing abilities.
    Yoshida A; Yamamoto M; Irie T; Hirayama F; Uekama K
    Chem Pharm Bull (Tokyo); 1989 Apr; 37(4):1059-63. PubMed ID: 2766408
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Selected Anionic β-Cyclodextrins on Persistence of Blood Glucose Lowering by Insulin Glargine after Subcutaneous Injection to Rats.
    Uehata K; Anno T; Hayashida K; Motoyama K; Higashi T; Hirayama F; Ono N; Pipkin JD; Uekama K; Arima H
    J Drug Deliv; 2011; 2011():195146. PubMed ID: 22187651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel inclusion complex of ibuprofen tromethamine with cyclodextrins: physico-chemical characterization.
    Al Omari MM; Daraghmeh NH; El-Barghouthi MI; Zughul MB; Chowdhry BZ; Leharne SA; Badwan AA
    J Pharm Biomed Anal; 2009 Oct; 50(3):449-58. PubMed ID: 19545961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative.
    Ishiguro T; Morishita E; Iohara D; Hirayama F; Wada K; Motoyama K; Arima H; Uekama K
    Int J Pharm; 2011 Oct; 419(1-2):161-9. PubMed ID: 21839823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility of 2-hydroxypropyl-beta-cyclodextrin in an intramuscular injectable preparation of nimodipine.
    Yoshida A; Yamamoto M; Itoh T; Irie T; Hirayama F; Uekama K
    Chem Pharm Bull (Tokyo); 1990 Jan; 38(1):176-9. PubMed ID: 2337940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement of solubility and oral bioavailability of 2-(N-cyanoimino)-5-[(E)-4-styrylbenzylidene]-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-beta-cyclodextrin.
    Hara T; Hirayama F; Arima H; Yamaguchi Y; Uekama K
    Chem Pharm Bull (Tokyo); 2006 Mar; 54(3):344-9. PubMed ID: 16508189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis.
    Jono H; Anno T; Motoyama K; Misumi Y; Tasaki M; Oshima T; Mori Y; Mizuguchi M; Ueda M; Shono M; Obayashi K; Arima H; Ando Y
    Biochem J; 2011 Jul; 437(1):35-42. PubMed ID: 21668413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sugar-appended polyamidoamine dendrimer conjugates with cyclodextrins as cell-specific non-viral vectors.
    Arima H; Motoyama K; Higashi T
    Adv Drug Deliv Rev; 2013 Aug; 65(9):1204-14. PubMed ID: 23602906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.